Microsoft has now shed 7% in a week to $397.36. The options market is screaming louder than anything in the lending data.
The put/call ratio hit 0.47 on June 10. That is four standard deviations above the 20-day mean of 0.35. It is the most defensive positioning the options market has printed in months — and it has held there for three consecutive sessions. Tuesday's note flagged the PCR at 3.9 standard deviations above average. It has pushed higher still.
Options traders shifted from near-52-week bullish to the most defensive posture in months in the space of a week. The prior week's report noted the PCR running near a bullish extreme at 0.34. It now sits at 0.47. The 52-week high is 0.85, so this is not a full panic — but the speed and persistence of the move is notable. Three days at or above 0.46, each with a z-score above 3.5. That kind of sustained deviation is unusual.
The stock fell 1.5% on Wednesday alone. It is down 10.6% from the weekly high hit during Computex week.
Cost to borrow rose 68% over the past week to 0.44%. That sounds dramatic. It is not. The absolute level remains trivially low. Availability is effectively unlimited — borrow supply is vast relative to demand. Short interest stands at 1.22% of free float. It is rising — up 15.7% over seven days — but the base is far too small to constitute a meaningful short thesis. This is incremental positioning, not conviction.
The CTB spike is a footnote, not the story.
The Street has not moved. TD Cowen, Cantor Fitzgerald, and Citizens all reiterated Buy-equivalent ratings in the past week. Wells Fargo raised its target to $650 from $625 on June 1 — the same day the stock was sliding. The consensus mean target sits at $561. At $397, that implies 41% upside. That gap has widened materially as the stock has fallen without any analyst capitulation.
July 30 earnings are the next hard catalyst. The last print saw the stock fall 5% on the day.
See the live data behind this article on ORTEX.
Open MSFT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
